After her doctor misdiagnosed her perimenopause as herpes, Halle Berry knew it was time to open a national conversation. Earlier this Women’s Health Month, the actress joined a group of U.S. senators outside the Capitol Building to call for more federal funding for research into a critical part of the female experience that should not be hard to fund, let alone discuss. “The shame has to be taken out of menopause,” she said. “We have to talk about this very normal part of our life that happens.”
Just having this public conversation is groundbreaking. Ten years ago, the word “menopause” was barely uttered. “Women’s health” as a category did not exist for patients, entrepreneurs, employers, or investors. You’d have been shocked to find fertility care, maternity benefits, or IVF offered by America’s largest employers. Back then, my industry—venture capital—did not even consider women’s health an investable category.
Against that backdrop, almost exactly 10 years ago, I met Kate Ryder. Then a former journalist, Kate wanted to tackle the infamously-bureaucratic, slow-moving healthcare industry–a system that is hesitant to adopt new technology and, until recently, treated women’s health just like men’s health, ignoring the complex hormonal changes throughout a woman’s life. In fact, the inclusion of women in clinical trials did not become law until the early 1990s.
Kate’s vision—for a healthcare experience that would put the female patient at the center of care for the first time—was incredibly compelling and visionary. My firm, Female Founders Fund, went on to write one of our first checks to Maven Clinic, getting a front-row seat as Kate built the first women’s health unicorn. Maven Clinic is now worth $1.35 billion and serves more than 2,000 employers, including giant corporations like Microsoft and AT&T. But more important than the statistics is that Kate convinced employers that it is imperative to provide better benefits for women, and she helped prove to venture investors—and the medical industry—that women’s health has massive potential as a business that is well worth the investment.
Since then, I’ve seen the tide shift as more and more founders and investors put money into women’s health. A great example: A few years ago, I was pitched by two women building a more holistic care model for pregnancy, combining the best aspects of obstetric care and midwifery care into an evidence-based birth program tailored to each mother’s unique wants and needs. And with the U.S. having the worst maternal mortality rate of all developed nations, the pregnancy and birthing experience needed to change. Adrianne and Elaine of Oula were convinced that there was a better solution, again putting the female patient experience at the center.
Oula has now raised more than $50 million in funding from investors, including Female Founders Fund, and has facilitated over 1,500 births with a 26% better C-section rate compared to New York City benchmarks and a 61% lower preterm birth rate—all while maintaining an NPS customer experience score greater than 90.
Just as encouraging are the successful startups that are not inside our portfolio.
Midi Health provides virtual care for women in menopause and perimenopause, and the results of this well-tailored care have been incredible. Around 91% of their patients report improving symptoms after just two months of care. Over 94% of patients see improvement in hot flashes in three months, 93% of patients report less insomnia in the first five months and 92% claim their moods improved in just two months. The company has raised over $100M to date, provides care in all 50 states, and now partners with major healthcare systems like Memorial Hermann and benefit-providers like Progyny and Cleo.
And there are many other examples over the last decade, such as Kindbody, Carrot, Clue, Alife Health,that show things are changing. Women are benefiting from improved solutions across a multitude of life experiences: menopause, IVF, endometriosis, fertility, hormone health, childbirth, osteoporosis, cancer diagnosis, and much more. The social momentum is building, too. Advocates like Elaine Welteroth and Serena Williams are raising awareness of critical issues of better maternal options with the launch of the Birth Fund earlier this year. Last year, President and Dr. Biden announced $100 million for women’s health initiatives and called on Congress to invest $12 billion in research—a move that was widely and rightly applauded. Of course, despite the progress, we still have a long way to go. Disproportionate funding is allocated toward diseases primarily affecting men, while the majority of medical professionals are still brushing off women’s pain instead of treating it.
But if there’s ever been a year to capitalize on the momentum of women, it’s this year; It’s right now, as the medical community finally begins to acknowledge women have evolving health needs across each stage of their lives.
Maternity care is ripe for innovation, yes, but it’s not the only area of women’s health that deserves better options. Look no further than the recent breakthroughs in the menopause space. For example, just last year, the FDA approved Veozah, an oral medication for the treatment of hot flashes, bringing a new drug to market that can serve as a potential alternative to hormone replacement therapy. Researchers are also exploring other major ideas, like whether collecting and freezing ovarian tissue during a woman’s 20s and 30s, only to transplant it back into the body years later, could restore pre-menopausal hormone production that could delay menopause. For too long, most OB-GYNs didn’t even receive formal training in menopause medicine—and, no surprise, most women didn’t receive treatment. Ignoring these women wasn’t just harmful—it was also leaving $600 billion on the table. Now, menopause companies like Midi, Elektra Health,and Amira are seizing that opportunity.
Beyond menopause, recent research has also unearthed disparities in all sorts of conditions, which could translate to market opportunities. Women disproportionately suffer from chronic pain, fibromyalgia, autoimmune disease, Alzheimer’s, migraines, and even anxiety and depression. Women with heart disease, diabetes, and chronic fatigue syndrome experience different symptoms than men do. Discomfort is such a routine part of womanhood—but with research and innovation, it really should not have to be. Models like the Metrodora Clinic, launched by Instacart CEO Fidji Simo, are providing a blueprint for how women should be treated in the medical world by taking a more holistic approach to complex neuro-immune diseases such as endometriosis, chronic fatigue syndrome, POTS, and more.
From an innovation perspective, we can also reimagine the sub-par tools and treatments we women have learned to tolerate all our lives. We’ve seen some exciting advances here, too, from a new device for IUD insertion to a probiotic that eases vaginal discomfort. But there are so many more areas—mammograms, IUDs, tampons, speculums, and birth control pills, to name a few—that need an upgrade. As a friend of mine put it recently, “If men had to get pap smears, a better solution would have been funded decades ago.”
More opportunities will mean more competition—and that’s a good thing. An infusion of new players will prove an even larger market opportunity, create healthy competition, and incentivize all players to provide better, more accessible care. I recently asked a founder if she’s concerned about a new entrant in the space she’s been leading for years. On the contrary: “Bring it on,” she said. “More competitors just validate our market.”
But while the private sector can start the flywheel, the public sector can solve problems that even the best startups alone can’t fix. To create true health equity, the government needs to step in to make these solutions viable for a much larger demographic. We need to see the launch of specific clinics devoted to women’s health. We need to mandate a physician curriculum for treating women’s needs, which ultimately leads to a new standard of care. We need solutions for women’s health treatments, wherever care is less accessible. From creating pathways to mitigate the shortages of doulas (and other key providers) to directing insurance providers to fully cover more women’s health treatments and procedures, we need government and philanthropic partnerships to bring women’s health into the modern era.
When even an A-list actress can’t find a doctor who can distinguish one extremely common health condition affecting women from a sexually transmitted disease, we know we have a long way to go. What we’re seeing today—some solutions, for some conditions, for some people—is just the beginning. We’ve made remarkable progress in identifying the needs of women and leveraging technology and talented entrepreneurs to build better solutions. Ten years from now, I hope women will have options as nuanced as they are, for every stage of their healthcare journey.
That would mean an explosion of innovation—and capital—in women’s health, the likes of which we’ve never seen. The moment to fund, and to found, is now. Women are primed for it.
Anu Duggal is the founding partner at Female Founders Fund, a venture capital firm that invests exclusively in female-founded companies.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.
